Cagrilintide is an innovative long-acting amylin analogue created by Novo Nordisk EJ. This dual agonist for amylin and calcitonin receptors introduces a new mechanism for weight management, equipping researchers with a powerful resource for studies on metabolic health.
Key Benefits
*Dual Receptor Activation: Effectively targets both amylin and calcitonin receptors to control appetite, improve satiety, and influence glucose metabolism.
*Clinically Proven Efficacy: Research has shown that Cagrilintide results in significant, dose-dependent weight loss, with more pronounced reductions at higher doses.
*Enhanced Metabolic Health: Using Cagrilintide has been linked to notable decreases in body weight and better metabolic indicators.
*Cost-Effective Research Tool: The 10mg vial presents a more economical choice for long-term research protocols, lowering the cost per milligram in comparison to higher doses.
Composition
*Active Ingredient: Cagrilintide
*Concentration: 10mg per vial.
*Form: Lyophilized peptide powder
Usage & Storage
Intended Use: For research purposes only
Storage: Keep the lyophilized powder in a cool, dry environment.
Once reconstituted, refrigerate at 2-8°C and utilize within the specified study timeframe.
